June 18th, 2020 | 08:40 CEST
BioNTech, Evotec, EXMceuticals - which stocks have the potential to double?
Experienced investors assume that the DAX, Germany's leading index, will still reach new highs in 2020. One of the best-known supporters of this scenario is the asset manager Dr. Jens Ehrhardt. Rising markets are supported by the measures taken by central banks and politicians - it is de facto the consequence of the increase in the money supply. This expected development will be of particular interest to those investors who have so far been on the sidelines and have to position themselves or reallocate.
time to read: 2 minutes
|
Author:
Mario Hose
ISIN:
CA30207T1049 , US09075V1026 , DE0005664809
Table of contents:
Author
Mario Hose
Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.
Tag cloud
Shares cloud
Pessimists seldom have reason to be happy
At the stock exchange, buyer and seller meet. The buyer side sees potential, the seller side often has a different opinion. However, the motives for sales can also be detached from the question of the expected potential, for example, if the portfolio has become unbalanced or a stop-mark has been reached. Anyone who has been active on the stock market for a longer period of time and has been following the media closely has certainly already noticed that the optimists have reasons to be happy about a longer period and the pessimists can only ever feel confirmed in a relatively small but violent time window.
Central banks are pointing the way
For example, the DAX rose from 3,588 points in 2009 to 13,795 points in 2020 - a full 10,207 points. In the heat of the Corona battle, it went down to 8,255 points within four weeks starting in February, but at the current level of around 12,300 points, a new high is almost within reach again. The pessimists have now largely fallen silent again after their four-week celebration. The power of the central banks should not be underestimated.
Gateway to the EU market
If you want to participate in the future, you should take a look at EXMceuticals. The company signed a letter of intent last week with an operating subsidiary of Plena Global Holdings Inc, a major producer and supplier of medical grade cannabis ingredients. According to the agreement, the processing plant in Portugal planned by EXMceuticals will be supplied with GMP-compliant THC distillate in the future. With this agreement, EXMceuticals reinforces its strategy to position itself as the "gateway" to the European market for existing manufacturers of legal cannabis.
Europe as a growth market
"The demand will explode in the next few years as the European cannabis industry continues to develop into one of the largest cannabis markets in the world and more countries require the use of EU GMP standards. Securing valuable sources of ingredients with consistent, large-scale suppliers such as Plena Global is more important than ever for the buildout of the EXM supply chain. (...)," said Jonathan Summers, Chief Executive Officer of EXM.
Health in focus
BioNTech remains the focus of investors waiting for a vaccine against Covid-19. The team of experts cooperates with pharmaceutical giant Pfizer, among others. In addition, the company pursues the development of preparations and therapies for the individual treatment of cancer.
The active ingredient expert Evotec was also able to attract attention with positive reports in recent weeks. The company is participating in a project in the USA that is intended to enable the rapid assessment of potential health and environmental risks resulting from chemicals. In addition, a partnership was entered into for the development of antibodies against the immunodeficiency virus HIV. The US government has budgeted a volume of around USD 318 million for this project.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.
The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.
